The cancer drug lomustine has been around since 1976, but a recent change in ownership and production has skyrocketed the price of the drug by 1,400%.
The FDA is trying to tempt generic brand drug producers into producing the drug, as the name brand has taken such a drastically steep price hike. For years, the drug was produced by Bristol-Myers Squibb Co., selling for $50 a capsule. But now, NextSource has begun charging $768 per capsule, after a series of price increases. Lomustine, or Gelostine as it is called by NextSource, does not have a generic competitor. It is used to treat brain tumors and Hodgkin Lymphoma. (source) 5:01 p.m. ET December 26, 2017